看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。. T9 e. f: b8 E
0 W% s n+ x, m1 ^9 ?, A
4 N0 |* Z) H ?Currently available feasibility data for possible combination strategies.
+ c/ r* D/ I' U9 b' B2 k* N& T4 j————————————————————————————————
- s% e3 U4 V* {8 lCombination Feasibility according to preliminary data / s0 V: F4 R( Q+ A& C# L
——————————————————————————————————: p% L6 Q7 {) S% c$ {' u
Bevacizumab + sorafenib Yes, reduced dose
5 \! S7 A$ A2 wBevacizumab + sunitinib† No 8 a/ H* J' X- l6 F: c4 W+ U
Bevacizumab + temsirolimus Yes 7 d! q. _* i3 G. B
Bevacizumab + everolimus Yes
3 \; I5 Q3 _: j3 q* Y( kSorafenib + sunitinib ? . d9 j3 m7 O$ q6 h& O) o( V
Sorafenib + temsirolimus Yes, reduced dose
. d5 Z$ Z6 h( V8 B3 u1 V1 h0 |$ G$ [Sorafenib + everolimus Yes, reduced dose
8 ^ o. _! S/ o3 q. zSunitinib + temsirolimus† No
% @) a# b. C {Sunitinib + everolimus ? . a& E5 q# r- k
Temsirolimus + everolimus ?
" @9 @" ^' P; U$ S+ E8 ^2 K! ?: Y————————————————————
! O4 h4 ? c$ `9 j" ?+ e. _1 [†Led to US FDA warning.
( G( ^/ v1 H2 ?8 l F2 D?: As yet unattempted combination.
' G/ S: B! ]4 G8 F |